Final outcome analysis from TUXEDO-1 trial is out
Elisa Agostinetto shared a paper by Rupert Bartsch et al. on X:
“Now out the final outcome analysis from TUXEDO-1 trial.
T-DXd in patients with active brain metastases produced prolonged intra and extra cranial disease control.
With 26.5 months median follow-up, mPFS was 21 months and mOS not reached.”
Source: Elisa Agostinetto/X
Elisa Agostinetto is a Clinical Research Fellow at the Institute Jules Bordet in Brussels, Belgium. She is also a Resident in Medical Oncology at Humanitas Research Hospital in Milan, Italy. Agostinetto specializes in Breast Cancer and Immuno-Oncology.
Authors: Rupert Bartsch, Anna Sophie Berghoff, Julia Furtner, Maximilian Marhold, Elisabeth Sophie Bergen, Sophie Roider-Schur, Maximilian Johannes Mair, Angelika Martina Starzer, Heidrun Forstner, Beate Rottenmanner, Marie-Bernadette Aretin, Karin Dieckmann, Zsuzsanna Bago-Horvath, Helmuth Haslacher, Georg Widhalm, Aysegül Ilhan-Mutlu, Christoph Minichsdorfer, Thorsten Fuereder, Thomas Szekeres, Leopold Oehler, Birgit Gruenberger, Georg Pfeiler, Christian Singer, Ansgar Weltermann, Luzia Berchtold, and Matthias Preusser.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023